Market capitalization | GBP1.01b |
Enterprise Value | GBP987.50m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.06 |
P/S ratio (TTM) P/S ratio | 1.09 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 9.91% |
Revenue (TTM) Revenue | GBP933.29m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
8 Analysts have issued a Indivior forecast:
8 Analysts have issued a Indivior forecast:
Sep '24 |
+/-
%
|
||
Revenue | 933 933 |
10%
10%
|
|
Gross Profit | 737 737 |
7%
7%
|
|
EBITDA | 219 219 |
195%
195%
|
EBIT (Operating Income) EBIT | 193 193 |
177%
177%
|
Net Profit | -1.13 -1.13 |
99%
99%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Head office | United Kingdom |
CEO | Mark Crossley |
Employees | 1,164 |
Founded | 2014 |
Website | indivior.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.